MARKET

BLRX

BLRX

Biolinerx
NASDAQ
0.2540
-0.0161
-5.96%
After Hours: 0.2550 +0.001 +0.39% 18:54 12/05 EST
OPEN
0.2700
PREV CLOSE
0.2701
HIGH
0.2788
LOW
0.2500
VOLUME
1.16M
TURNOVER
--
52 WEEK HIGH
1.890
52 WEEK LOW
0.2500
MARKET CAP
21.36M
P/E (TTM)
-0.3330
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BLRX last week (1125-1129)?
Weekly Report · 3d ago
JonesTrading Reaffirms Their Buy Rating on Bioline RX Ltd Sponsored ADR (BLRX)
TipRanks · 11/26 17:45
BioLineRx Reports Strategic Moves in Q3 2024
TipRanks · 11/26 03:55
BioLine RX Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 11/25 17:23
BioLine RX Price Target Cut to $9.00/Share From $21.00 by HC Wainwright & Co.
Dow Jones · 11/25 17:23
HC Wainwright & Co. Maintains Buy on BioLine Rx, Lowers Price Target to $9
Benzinga · 11/25 17:13
BioLineRx price target lowered to $9 from $21 at H.C. Wainwright
TipRanks · 11/25 17:00
BRIEF-BioLineRx Reports Q3 2024 Financial Results
Reuters · 11/25 14:42
More
About BLRX
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Webull offers BioLine RX Ltd - ADR stock information, including NASDAQ: BLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BLRX stock methods without spending real money on the virtual paper trading platform.